Pedro Gonzalez-Alegre, MD, PhD
Department of Neurology
800 Spruce Street
Philadelphia, PA 19107
University of Malaga Medical School, Málaga (Spain), 1996.
University of Malaga Medical School, Málaga (Spain), 2009.
Intern, Department of Medicine, Saint Vincent Hospital, 1998-1999.
Resident, Department of Neurology, University of Iowa , 1999-2002.
Fellow, Movement Disorders/Neurogenetics, University of Iowa , 2002-2004.
Educational Commission for Foreign Medical Graduates, 1997.
American Board of Psychiatry and Neurology (recertification March 2013), 2003.
Description of Clinical ExpertiseDr. Pedro Gonzalez-Alegre is a physician-scientist certified by the American Board of Psychiatry and Neurology and with subspecialty training in Movement Disorders/Neurogenetics. After completing his residency and fellowship training at the University of Iowa, he joined the faculty at that institution where he reached the rank of Associate Professor with tenure. In 2014, he was recruited to the Department of Neurology at the University of Pennsylvania. He has been elected to the Best Doctors in America list every year since 2009. He is the founding director of the Penn HD Center since 2015, gaining designation as a Center of Excellence of the HDSA (Huntington’s Disease Society of America) in 2016. He also launched a new Neurogenetics Clinic at Penn in 2015.
Description of Other ExpertiseDr. Gonzalez-Alegre has devoted significant efforts to education. He has been the advisor of several graduate students that successfully obtained their PhD, mentored numerous undergraduate and medical students, neurology residents and fellows, and participated in multiple local, national and international educational programs related to neurology. He was named Associate Director of the Neurology Residency Program at the University of Iowa in 2009, Residency Program Director and acting Vice-Chair for Education in 2012, Chair of the Seminar Committee and Member of the Executive Committee of the Interdisciplinary Program in Neuroscience at the University of Iowa in 2012. His educational efforts were rewarded by the 2009 and 2012 Medical Education Faculty Award in Neurology of the Carver College of Medicine at the University of Iowa and the 2014 Best Teacher Award from the Neurology Residents at UI.
Description of Research ExpertiseDr. Gonzalez-Alegre is a highly committed clinician-scientist who directs a laboratory devoted to the investigation of the neurobiological bases and therapeutics of dystonia. For his research efforts, funded through federal and private sources, he has been recognized with 2003 S Weir Mitchell Award of the American Academy of Neurology, the 2004 Junior Award for Excellence in Basic Science Research from the Movement Disorders Society, the 2012 Jon Stolk Award in Movement Disorders from the American Academy of Neurology, and the 2012 Stanley Fahn Award from the Dystonia Medical Research Foundation. He is also Co-Director for Clinical Programs of the Raymond G. Perelman Center for Cellular & Molecular Therapy at the Children Hospital of Philadelphia, involved in translational efforts to advance novel molecular therapies for various neurological diseases to early phase clinical trials.
Selected PublicationsHamedani A, Bardakjian T, Balcer L, Gonzalez-Alegre P.: Contrast acuity and the King-Devick test in Huntington’s Disease. Neuro-Ophthalmology in press, 2020.
64. Hamedani A, Bardakjian T, Balcer L, Gonzalez-Alegre P. : Inpatient gastrostomy in Huntington's disease: Nationwide analysis of utilization 3 and outcomes compared to amyotrophic lateral sclerosis. Clin Parkinsonism Relat Disord in press, 2020.
Pedro Gonzalez-Alegre; Genevieve Beauvais; Janine Martin; Rick J. Koch; Ruth H. Walker; Jyoti C. Patel; Margaret E. Rice; Michelle E. Ehrlich.: A novel transgenic mouse model to investigate the cell-autonomous effects of torsinA(
Pedro Gonzalez-Alegre.: Recent advances in molecular therapies for neurological disease: triplet repeat disorders. Hum Mol Genet 28(R1): R80-R87, October 2019.
Joseph Park; Scott M. Damrauer; Aris Baras; Jeffrey G. Reid; John D. Overton; Pedro Gonzalez-Alegre.: Epidemiology of DYT1 dystonia: estimating prevalence via genetic ascertainment. Neurology Genetics 5(5): e358, September 2019.
Tanya M. Bardakjian, Jennifer Klapper, Adrianna Carey, Julia Wood, Meredith Pauly, Kelly Gasper; Kathy Lawler, Baochan Tran; Yuliis Bell; Alex Zwil, Pedro Gonzalez-Alegre: Addressing the value of multidisciplinary clinical care in Huntington's Disease: a snapshot of a new Huntington's Disease Center. Journal of Huntington Disease 8(4): 501-507, September 2019.
Gonzalez-Alegre P.: Advances in cell biology of dystonia: Focus on torsinA Neurobiology of Disease 127: 233-241, July 2019.
Narendra DP, Isonaka R, Nguyen D, Schindler AB, Kokkinis AD, Ehrlich D, Bardakjian TM, Goldstein DS, Liang TW, Gonzalez-Alegre P.: Peripheral synucleinopathy in a DJ1 patient with Parkinson disease, cataracts, and hearing loss. . Neurology 92(23): 1113-1115, June 2019.
Beauvais G, Watson JL, Aguirre JA, Tecedor L, Ehrlich ME, Gonzalez-Alegre P.: Efficient RNA interference-based knockdown of mutant torsinA reveals reversibility of PERK-eIF2α pathway dysregulation in DYT1 transgenic rats in vivo. Brain Research 1706: 24-31, March 2019.
Bardakjian TM, Faulkner-Naczi K, Gonzalez-Alegre P: Attitudes of Potential Subjects Towards Molecular Therapy Trials in Huntington's Disease. Journal of Huntington's Disease 8(1): 79, February 2019.